Corcept Therapeutics (NASDAQ:CORT) Stock: Insider Sean Maduck Sells 11,841 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 11,841 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $81.42, for a total value of $964,094.22. Following the completion of the sale, the insider owned 9,938 shares in the company, valued at $809,151.96. This trade represents a 54.37% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Sean Maduck also recently made the following trade(s):

• On Tuesday, November 3rd, Sean Maduck sold 13,159 shares of Corcept Therapeutics stock. The shares were sold at an average price of $82.25, for a total value of $1,082,327.75.
• On Friday, October 2nd, Sean Maduck sold 24,587 shares of Corcept Therapeutics stock. The stock was sold at an average price of $116.28, for a total value of $2,858,976.36.
• On Thursday, October 1st, Sean Maduck sold 413 shares of Corcept Therapeutics stock. The stock was sold at an average price of $115.54, for a total value of $47,718.02.
• On Tuesday, September 1st, Sean Maduck sold 25,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $114.43, for a total value of $2,860,750.00.
• On Tuesday, August 25th, Sean Maduck sold 30,955 shares of Corcept Therapeutics stock. The shares were sold at an average price of $125.58, for a total value of $3,887,328.90.
• On Friday, August 14th, Sean Maduck sold 3,664 shares of Corcept Therapeutics stock. The shares were sold at an average price of $114.49, for a total value of $419,491.36.
• On Monday, August 10th, Sean Maduck sold 1,031 shares of Corcept Therapeutics stock. The shares were sold at an average price of $114.52, for a total value of $118,070.12.

Corcept Therapeutics Trading Down 9.6%

Shares of NASDAQ CORT opened at $71.63 on Friday. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $126.38. The firm has a market capitalization of $7.84 billion, a price-to-earnings ratio of 56.40 and a beta of 0.54. The business has a 50-day moving average of $108.46 and a 200-day moving average of $75.47.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.17. The company had revenue of $340.47 million for the quarter, compared to analysts’ expectations of $339.12 million. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. Corcept Therapeutics’s revenue for the quarter was up 64.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.16 earnings per share. On average, analysts predict that Corcept Therapeutics Incorporated will post 1.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CORT. Zacks Research lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 27th. Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Piper Sandler reaffirmed an “overweight” rating and set a $173.00 price objective (up from $165.00) on shares of Corcept Therapeutics in a report on Wednesday. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a research report on Monday, July 27th. Finally, Canaccord Genuity Group increased their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Corcept Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $139.50.

Hedge Funds Weigh In On Corcept Therapeutics

A number of large investors have recently modified their holdings of CORT. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Corcept Therapeutics in the second quarter worth approximately $27,000. State of Wyoming grew its position in Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 186 shares during the last quarter. Provenance Wealth Advisors LLC bought a new position in Corcept Therapeutics during the third quarter valued at approximately $38,000. Gould Capital LLC grew its position in Corcept Therapeutics by 66.7% during the first quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 400 shares during the last quarter. Finally, Fulcrum Asset Management LLP raised its stake in shares of Corcept Therapeutics by 520.7% during the third quarter. Fulcrum Asset Management LLP now owns 571 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 479 shares in the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Third-quarter revenue climbed 64% year over year to about $340.5 million, while earnings of $1.01 per share beat estimates. Higher Korlym sales and growing Lifyorli uptake contributed to the results. Article: CORT’s Q3 Earnings Beat
• Positive Sentiment: Piper Sandler reaffirmed its “overweight” rating and raised its price target to $173 from $165. Article: Piper Sandler rating
• Neutral Sentiment: Corcept is awaiting a December 17 FDA decision on relacorilant and has outlined a long-term opportunity of $3 billion to $5 billion in Cushing’s revenue by 2030; both depend on regulatory and commercial success. Article: Relacorilant decision and revenue target
• Negative Sentiment: Shares have faced pressure despite the earnings beat as investors focused on company guidance. HC Wainwright also lowered its Q1 2027 EPS estimate to $0.60 from $0.74, although it kept a Buy rating and $165 price target. Article: Shares fall on guidance
• Negative Sentiment: Two insiders reported sizable sales: Roberto Vieira sold 8,333 shares, reducing his position by about 68%, while Sean Maduck sold shares in two transactions that cut his holdings by more than half. Insider sales can raise concerns, though they do not necessarily indicate a change in company prospects. Article: Corcept insider sale

About Corcept Therapeutics

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.